Orchestra BioMed Holdings (OBIO) Free Cash Flow (2021 - 2026)
Orchestra BioMed Holdings (OBIO) reported Free Cash Flow of -$22.4 million for Q1 2026, down 33.62% year-over-year from -$33.7 million in Q1 2025, and down 1027.18% on a QoQ basis from -$2.0 million in Q4 2025.
Orchestra BioMed Holdings (OBIO) has 6 years of Free Cash Flow data on file, last reported at -$22.4 million in Q1 2026.
- Quarterly Free Cash Flow fell 33.62% year-over-year to -$22.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$54.8 million (down 0.74% YoY) and the FY2025 annual result came in at -$49.1 million, up 3.37% from the prior year.
- Free Cash Flow fell to -$22.4 million in Q1 2026 per OBIO's latest filing, from -$2.0 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$2.0 million in Q4 2025 and bottomed at -$22.4 million in Q1 2026.
- The 5-year median for Free Cash Flow is -$11.0 million (2023), against an average of -$11.7 million.
- The widest annual swing landed in 2022, when Free Cash Flow plunged 30411.53%; it then soared 85.63% in 2025.
- Tracing OBIO's Free Cash Flow over 5 years: stood at -$8.8 million in 2022, then declined by 24.7% to -$11.0 million in 2023, then dropped by 25.79% to -$13.8 million in 2024, then soared by 85.63% to -$2.0 million in 2025, then tumbled by 1027.18% to -$22.4 million in 2026.
- Per Business Quant, the three latest OBIO Free Cash Flow figures stand at -$22.4 million (Q1 2026), -$2.0 million (Q4 2025), and -$14.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Orchestra BioMed Holdings | 245.24 Mn | 255.02 Mn | 78,000.00 | -22.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.35 Mn |
| Mar 31, 2026 | -22.35 Mn |
| Dec 31, 2025 | -1.98 Mn |
| Dec 31, 2025 | -1.98 Mn |
| Sep 30, 2025 | -14.86 Mn |
| Sep 30, 2025 | -14.86 Mn |
| Jun 30, 2025 | -15.56 Mn |
| Jun 30, 2025 | -15.56 Mn |
| Mar 31, 2025 | -16.73 Mn |
| Mar 31, 2025 | -16.73 Mn |
| Dec 31, 2024 | -13.80 Mn |
| Dec 31, 2024 | -13.80 Mn |
| Sep 30, 2024 | -13.61 Mn |
| Sep 30, 2024 | -13.61 Mn |
| Jun 30, 2024 | -10.21 Mn |
| Jun 30, 2024 | -10.21 Mn |
| Mar 31, 2024 | -13.22 Mn |
| Mar 31, 2024 | -13.22 Mn |
| Dec 31, 2023 | -10.97 Mn |
| Dec 31, 2023 | -10.97 Mn |
| Sep 30, 2023 | -10.30 Mn |
| Sep 30, 2023 | -10.30 Mn |
| Jun 30, 2023 | -10.52 Mn |
| Jun 30, 2023 | -10.52 Mn |
| Mar 31, 2023 | -14.42 Mn |
| Mar 31, 2023 | -14.42 Mn |
| Dec 31, 2022 | -8.80 Mn |
| Dec 31, 2022 | -8.80 Mn |
| Sep 30, 2022 | -7.48 Mn |
| Sep 30, 2022 | -7.48 Mn |
| Jun 30, 2022 | -8.23 Mn |
| Jun 30, 2022 | -8.23 Mn |
| Mar 31, 2022 | -5.37 Mn |
| Mar 31, 2022 | -5.37 Mn |
| Dec 31, 2021 | -28,835.00 |
| Dec 31, 2021 | -28,835.00 |
| Sep 30, 2021 | -128,010.00 |
| Sep 30, 2021 | -128,010.00 |
| Jun 30, 2021 | -39,143.00 |
| Jun 30, 2021 | -39,143.00 |
| Mar 31, 2021 | -76,374.00 |
| Mar 31, 2021 | -76,374.00 |